文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

法匹拉韦和/或硝唑尼特:在IMSS医护人员、家庭成员及患者中开展的COVID-19早期治疗随机双盲2×2设计安慰剂对照试验(FANTAZE)

Favipiravir and/or nitazoxanide: a randomized, double-blind, 2×2 design, placebo-controlled trial of early therapy in COVID-19 in health workers, their household members, and patients treated at IMSS (FANTAZE).
PubMed 文献 · Trials · 2022-07-22

该试验为IIA期随机双盲2×2设计安慰剂对照干预试验,在墨西哥社会安全研究所(IMSS)的医护人员、家庭成员及患者中评估法匹拉韦联合或不联合硝唑尼特早期治疗COVID-19。主要结局为治疗5天后上呼吸道病毒载量差异,次要结局包括住院、重大疾病和死亡、药代动力学及病毒基因突变率影响。

要点

  • 法匹拉韦联合或不联合硝唑尼特用于COVID-19早期治疗,主要结局为治疗5天后上呼吸道病毒载量差异。
  • 试验为IIA期随机双盲2×2设计安慰剂对照干预试验,按性别、肥胖、症状、吸烟、合并症及疫苗接种状态分层随机1:1。
  • 若法匹拉韦联合硝唑尼特显示出重要抗病毒效果且无显著毒性,将为在高风险人群中开展更大规模试验提供有力依据。

核心结论

  • 若法匹拉韦联合硝唑尼特显示出重要抗病毒效果且无显著毒性,将为在住院或重症监护入院高风险人群(如老年人和/或有合并症且早期疾病者)中开展更大规模试验提供有力依据。

研究设计与样本

  • IIA期随机、双盲、2×2设计、安慰剂对照、干预性试验。
  • 参与者按性别、肥胖、有症状或无症状、当前吸烟状态、合并症存在与否及是否接种疫苗分层后1:1随机。
  • 参与者和研究者均对治疗分配设盲(双盲)。

关键数值与推荐

  • 主要结局为治疗5天后上呼吸道病毒载量差异。
  • 次要结局包括住院、重大疾病和死亡、药代动力学及抗病毒治疗对病毒基因突变率的影响。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The 2020 pandemic of SARS-CoV-2 causing COVID-19 disease is an unprecedented global emergency. COVID-19 appears to be a disease with an early phase where the virus replicates, coinciding with the first presentation of symptoms, followed by a later 'inflammatory' phase which results in severe disease in some individuals. It is known from other rapidly progressive infections such as sepsis and influenza that early treatment with antimicrobials is associated with a better outcome. The hypothesis is that this holds for COVID-19 and that early antiviral treatment may prevent progression to the later phase of the disease. METHODS: Trial design: Phase IIA randomised, double-blind, 2 × 2 design, placebo-controlled, interventional trial. RANDOMISATION: Participants will be randomised 1:1 by stratification, with the following factors: gender, obesity, symptomatic or asymptomatic, current smoking status presence or absence of comorbidity, and if the participant has or has not been vaccinated. BLINDING: Participants and investigators will both be blinded to treatment allocation (double-blind). DISCUSSION: We propose to conduct a proof-of-principle placebo-controlled clinical trial of favipiravir plus or minus nitazoxanide in health workers, their household members and patients treated at the Mexican Social Security Institute (IMSS) facilities. Participants with or without symptomatic COVID-19 or who tested positive will be assigned to receive favipiravir plus nitazoxanide or favipiravir plus nitazoxanide placebo. The primary outcome will be the difference in the amount of virus ('viral load') in the upper respiratory tract after 5 days of therapy. Secondary outcomes will include hospitalization, major morbidity and mortality, pharmacokinetics, and impact of antiviral therapy on viral genetic mutation rate. If favipiravir with nitazoxanide demonstrates important antiviral effects without significant toxicity, there will be a strong case for a larger trial in people at high risk of hospitalization or intensive care admission, for example older patients and/or those with comorbidities and with early disease. TRIAL REGISTRATION: ClinicalTrials.gov NCT04918927 . Registered on June 9, 2021.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Smith T, Hoyo-Vadillo C, Adom AA, et al. Favipiravir and/or nitazoxanide: a randomized, double-blind, 2×2 design, placebo-controlled trial of early therapy in COVID-19 in health workers, their household members, and patients treated at IMSS (FANTAZE). Trials. 2022. PMID: 35869526. doi:10.1186/s13063-022-06533-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。